Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CssBA+dmLT Vaccine Against ETEC in Healthy Adults
NCT06692907Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2025
- Primary completion
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CssBA and dmLT in enterotoxigenic Escherichia coli infection (4 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number and percentage of participants experiencing local solicited AEs at 7 days, Number and percentage of participants experiencing MAAEs at 6 months and 4 more. Started Mar 2025; status: completed.
02
Drugs
CssBAdmLT
03
Conditions
enterotoxigenic Escherichia coli infection
Beyond the preview
Go deeper on NCT06692907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06692907.